Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva

Brooke E. Howitt, Heather H. Sun, Margaretha G.M. Roemer, Alyssa Kelley, Bjoern Chapuy, Emeline Aviki, Christine Pak, Courtney Connelly, Evisa Gjini, Yunling Shi, Larissa Lee, Akila Viswanathan, Neil Horowitz, Donna Neuberg, Christopher P. Crum, Neal L. Lindeman, Frank Kuo, Azra H. Ligon, Gordon J. Freeman, F. Stephen HodiMargaret A. Shipp, Scott J. Rodig

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


IMPORTANCE Patients with squamous cell carcinoma (SCC) of the cervix or vulva have limited therapeutic options, and the potential for immunotherapy for this population has not been evaluated. Recent trials suggest that tumors with a genetic basis for PD-1 (programmed cell death protein 1) ligand expression are highly sensitive to therapeutic antibodies targeting PD-1. OBJECTIVE To determine the genetic status of CD274 (encoding PD-L1 [programmed cell death 1 ligand 1]) and PDCD1LG2 (encoding PD-L2 [programmed cell death 1 ligand 2]) in SCCs of the cervix and vulva and to correlate the findings with PD-L1 protein expression. DESIGN, SETTING, AND PARTICIPANTS We performed fluorescence in situ hybridization (FISH) using probes targeting CD274, PDCD1LG2, and the centromeric portion of chromosome 9, and immunohistochemistry (IHC) using an antibody recognizing PD-L1 on formalin-fixed, paraffin-embedded (FFPE) biopsy specimens from 48 cervical SCCs and 23 vulvar SCCs. MAIN OUTCOMES AND MEASURES Tumorswere categorized according to the genetic abnormality in CD274 and PDCD1LG2 (coamplification > cogain > polysomy > disomy) as detected by FISH, and evaluated on a semiquantitative scale (modified H score, the product of the percentage of tumor cells with positive staining and the maximum intensity of positive staining) for PD-L1 protein expression as detected by IHC. RESULTS Overall, 71 samples of FFPE tissue from cases of cervical SCCs (n = 48) and vulvar SCCs (n = 23) were retrieved from the archives of Brigham andWomen's Hospital and included in this study.We observed cogain or coamplification of CD274 and PDCD1LG2 in 32 of 48 cervical SCCs (67%) and 10 of 23 vulvar SCCs (43%). Median PD-L1 protein expression was highest among tumors with CD274 and PDCD1LG2 coamplification and lowest among tumors with disomy. CONCLUSIONS AND RELEVANCE Recurrent copy number gain of the genes encoding the PD-1 ligands provides a genetic basis for PD-L1 expression in a subset of cervical and vulvar SCCs and identifies a class of patients that are rational candidates for therapies targeting PD-1.

Original languageEnglish (US)
Pages (from-to)518-522
Number of pages5
JournalJAMA Oncology
Issue number4
StatePublished - Apr 2016
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva'. Together they form a unique fingerprint.

Cite this